Albanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Hyaluronidase for Trigger Point Injection in Myofascial Pain Syndrome

Vetëm përdoruesit e regjistruar mund të përkthejnë artikuj
Identifikohuni Regjistrohu
Lidhja ruhet në kujtesën e fragmenteve
StatusiPërfunduar
Sponsorët
Samsung Medical Center

Fjalë kyçe

Abstrakt

Myofascial pain syndrome (MPS) is the most common cause of persistent regional pain characterized by myofascial trigger points. Trigger point injection (TPI) using local anesthetics is one of the most effective methods for treatment of MPS, and steroids or botulinum toxin can be added to local injections .
Recent study suggested that the hyaluronan (HA) could be the basis of myofascial pain. HA within the deep fascia facilitates the free sliding of two adjacent fibrous fascial layers. If the HA assumes a more packed conformation, or more generally, if the loose connective tissue inside the fascia alters its density, the behavior of the entire deep fascia and the underlying muscle would be compromised.
The investigators anticipated that hyaluronidase could decrease the viscosity of HA near the muscle and fascia of trigger points. Meanwhile, hyaluronidase is thought to promote the spread of local anesthetic solution by hydrolyzing glycosidic bonds within HA. Hyaluronidase was shown to be effective in retro- and peribulbar block for ophthalmologic surgery or reducing tissue edema in dermatology, and adhesiolysis for some interventional pain managements.
However, the effect of the addition of hyaluronidase to local anesthetics during TPI has not been studied. The investigators aimed to compare the efficacy of TPI with the addition of hyaluronidase compared to local anesthetic alone on pain and quality of life in MPS patients.

Përshkrim

Study approval was obtained from Institutional Review Board (IRB) of Samsung medical center, and written informed consent was obtained from all participants.

The required sample size was determined by power analysis on the basis of a previous study. The primary outcome was pain intensity in the posterior neck and upper back after TPI using verbal numerical rating scale (VNRS). The standard deviation of VNRS was assumed to be 20. Power calculations indicated that detecting 20 points difference in VNRS between the two groups (with α = 0.05 and β = 0.1) would require a sample of 29 subjects for each group. To account for dropouts, 33 subjects were recruited for each group.

Group L received TPI with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline. Group H received TPI with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml. The investigators monitored vital sign and any signs of complications such as bleeding, hematoma, allergic reactions for 30 minutes. Treatment efficacy was evaluated by one of the authors (J.W.C.) using VNRS. To reduce bias, this evaluator and the participants were not informed of the assigned group.

Patients' characteristics such as age, height, weight, BMI and pretreatment neck disability index (NDI) and brief pain inventory (BPI) were analyzed by independent t-test. The sex distribution was analyzed by the chi-square test. P values were corrected by Bonferroni's method. Pretreatment VNRS and the duration of pain were evaluated by the Wilcoxon two-sample test. Repeated measures ANOVA was used to compare changes in the VNRS over time between the two groups. Pre- and post-TPI changes in NDI and BPI were compared between the two groups with the Wilcoxon signed rank test and the independent t-test, respectively. All analyses were performed with SPSS 18.0 (SPSS Inc., Chicago, IL, USA) statistical software. Significance was assumed for P values of less than 0.05.

Datat

Verifikuar së fundmi: 10/31/2014
Paraqitur së pari: 11/10/2014
Regjistrimi i vlerësuar u dorëzua: 11/12/2014
Postuar së pari: 11/17/2014
Përditësimi i fundit i paraqitur: 11/12/2014
Përditësimi i fundit i postuar: 11/17/2014
Data e fillimit të studimit aktual: 03/31/2010
Data e vlerësuar e përfundimit primar: 03/31/2011
Data e vlerësimit të përfundimit të studimit: 04/30/2011

Gjendja ose sëmundja

Myofascial Pain Syndrome

Ndërhyrja / trajtimi

Drug: trigger point injection

Faza

-

Grupet e krahëve

KrahNdërhyrja / trajtimi
Experimental: Lidocaine
Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
Experimental: Hyaluronidase
Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml

Kriteret e pranimit

Moshat e pranueshme për studim 25 Years Për të 25 Years
Gjinitë e pranueshme për studimAll
Pranon Vullnetarë të Shëndetshëmpo
Kriteret

Inclusion Criteria:

- Adults

- Aged 25-75 years

- Diagnosed with myofascial pain syndrome affecting both trapezius muscles

Exclusion Criteria:

- History of allergy to lidocaine or hyaluronidase

- Anticoagulant medication or antiplatelet agent within 5 days before the study

- Analgesic medication, including non-steroidal anti-inflammatory drugs, tramadol, acetaminophen, or opioids within 5 days of the study

- Pain related to trauma within 6 months before the study

- History of cervical or shoulder surgery

- TPI within 3 months in the same region

- Fibromyalgia

- Cervical radiculopathy or myelopathy

- Obesity, defined as body mass index of 27.5 or higher

- Other medical or psychological conditions (cancer, rheumatoid arthritis, endocrine disease, major depression, schizophrenia)

Rezultati

Masat Kryesore të Rezultateve

1. Degree of pain as measured by the verbal numerical rating scale [within 2 weeks after intervention]

Bashkohuni në faqen
tonë në facebook

Baza e të dhënave më e plotë e bimëve medicinale e mbështetur nga shkenca

  • Punon në 55 gjuhë
  • Kurime bimore të mbështetura nga shkenca
  • Njohja e bimëve nga imazhi
  • Harta GPS interaktive - etiketoni bimët në vendndodhje (së shpejti)
  • Lexoni botime shkencore në lidhje me kërkimin tuaj
  • Kërkoni bimë medicinale nga efektet e tyre
  • Organizoni interesat tuaja dhe qëndroni në azhurnim me kërkimet e lajmeve, provat klinike dhe patentat

Shkruani një simptomë ose një sëmundje dhe lexoni në lidhje me barërat që mund të ndihmojnë, shtypni një barishte dhe shikoni sëmundjet dhe simptomat që përdoren kundër.
* I gjithë informacioni bazohet në kërkimin shkencor të botuar

Google Play badgeApp Store badge